Around half of all human tumours carry mutant p53. This allows escape from p53-induced
cell cycle arrest and apoptosis. Many tumours express mutant p53 proteins at elevated …

Since its discovery in 1979, p53 has become the focus of intensive cancer-based research
in laboratories around the world. The p53 protein mediates critical cellular functions …

More than half of all human tumors express mutant forms of p53, with the ovary, lung,
pancreas, and colorectal cancers among the tumor types that display the highest prevalence …

Anticancer nucleoside analogs (eg, ara-C, gemcitabine, fludarabine) induce apoptosis by
incorporation into DNA. Removal of incorporated analogs from DNA by 3'-5'exonucleases is …

Cell cycle arrest coupled with hyper-active mTOR leads to cellular senescence. While
arresting cell cycle, high levels of p53 can inhibit mTOR (in some cell lines), thus causing …

The p53 tumor suppressor gene plays an important role in protecting cells from developing
undesirable proliferation. The mutant p53 gene or malfunctioning p53 protein found in more …

Objectives For the past three decades of research, p53 has been identified as one of the
most targetable molecules for developing anticancer treatments. This tumour suppressor …

Recent advances in the field of pharmacological activation of the p53 tumor suppressor are
beginning to be translated into the clinic. In addition, small molecules that activate p53 …

A powerful tumor suppressor–p53 protein is a transcription factor which plays a critical role
in eliciting cellular responses to a variety of stress signals, including DNA damage, hypoxia …

Inactivation of p53 function is a common event in cancer. Approximately 50% of human
tumours express mutant p53 and there is evidence that in others, including many childhood …